TWC
OVID icon

TD Waterhouse Canada’s Ovid Therapeutics OVID Stock Holding History

TD Waterhouse Canada’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80 Hold
30
– – ﹤0.01% 2327
2026
Q1 		$65 Hold
30
– – ﹤0.01% 2245
2025
Q4 		$49 Hold
30
– – ﹤0.01% 1998
2025
Q3 		$41 Hold
30
– – ﹤0.01% 2020
2025
Q2 		$10 Hold
30
– – ﹤0.01% 1970
2025
Q1 		$9 Hold
30
– – ﹤0.01% 1927
2024
Q4 		$28 Hold
30
– – ﹤0.01% 1930
2024
Q3 		$34 Buy
+30
New +$31 ﹤0.01% 1854

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TD Waterhouse Canada's OVID Position: Q2 2026 in Review

TD Waterhouse Canada held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 30 shares worth $80. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

TD Waterhouse Canada first reported a position in OVID in Q3 2024 and has held it in 8 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • TD Waterhouse Canada held 30 shares of Ovid Therapeutics worth $80 as of Q2 2026.
  • TD Waterhouse Canada left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2327 holding.
  • TD Waterhouse Canada first reported a position in Ovid Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.